Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes
| Autor: | Soo Jin Yang, Jae Hyeon Kim, Sung Woo Park, Kwang-Won Kim, Cheol-Young Park, Sang-Man Jin, Bae Jun Oh, Jung Mook Choi, Suel Lee |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Rats Inbred OLETF Adipose tissue Type 2 diabetes Rosiglitazone Eating Endocrinology & Metabolism Insulin resistance Rimonabant Piperidines Receptor Cannabinoid CB1 Internal medicine Diabetes mellitus Insulin-Secreting Cells Glucose Intolerance medicine Animals Adiposity Cell Proliferation geography geography.geographical_feature_category Adiponectin islet business.industry General Medicine Cannabinoid receptor CB1 medicine.disease Islet Rats Endocrinology Diabetes Mellitus Type 2 rimonabant Pyrazoles Thiazolidinediones Original Article type 2 diabetes Insulin Resistance business medicine.drug |
| Zdroj: | Yonsei Medical Journal |
| ISSN: | 1976-2437 |
| Popis: | Purpose Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. Materials and Methods After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). Results Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|